CV-6209

• UNSPSC Description:

  CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats[1].

• Target Antigen:

  Platelet-activating Factor Receptor (PAFR)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/cv-6209.html

• Purity:

  98.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC[N+]1=CC=CC=C1CN(C(C)=O)C(OCC(OC)COC(NCCCCCCCCCCCCCCCCCC)=O)=O.[Cl-]

• Molecular Weight:

  642.31

• References & Citations:

  [1]Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8.|[2]Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017;27(3):161-168.|[3]Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352(3):541-51.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  100488-87-7